Publications (53) Edel del Barco Morillo publications

filter_list Internal Medicine

2024

  1. Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry

    Clinical and Translational Oncology, Vol. 26, Núm. 12, pp. 3218-3225

  2. COMPLICATIONS SECONDARY TO THE USE OF SGLT2 INHIBITORS IN ONCOLOGICAL PATIENTS: A SERIES OF 5 CASES

    European Journal of Case Reports in Internal Medicine, Vol. 11, Núm. 1

  3. Cancer-Associated Thrombotic Microangiopathy: Literature Review and Report of Five Cases

    Life, Vol. 14, Núm. 7

  4. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

  5. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer

    International Journal of Molecular Sciences, Vol. 25, Núm. 4

  6. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663

  7. Oncología clínica coord.

    Arán

2023

  1. Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

    ERJ Open Research, Vol. 9, Núm. 6

  2. Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis

    Chinese Clinical Oncology, Vol. 12, Núm. 6

  3. Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

    Translational Lung Cancer Research, Vol. 12, Núm. 10, pp. 2113-2128

  4. The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients

    Diagnostics, Vol. 13, Núm. 14

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

  3. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

    Oral Oncology, Vol. 134

  4. Severe Hyponatremia Masking Central Diabetes Insipidus in a Patient with a Lung Adenocarcinoma

    Case Reports in Oncology, Vol. 15, Núm. 1, pp. 91-98

  5. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Journal for immunotherapy of cancer, Vol. 10, Núm. 9

2021

  1. Biomarcadores moleculares y celulares. Implicaciones en la terapia dirigida

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 25, pp. 1418-1423

  2. Carcinoma de pulmón no microcítico

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 25, pp. 1377-1387

  3. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8

  4. Cáncer de pulmón microcítico

    Medicine: Programa de Formación Médica Continuada Acreditado, Serie 13, Núm. 25, pp. 1369-1376